Venture firm Dimension Capital has closed its third fund at $800 million, a 60% increase over its previous vehicle. The firm focuses on startups merging biotechnology with software and AI. This capital raise highlights growing institutional interest in deep-tech sectors, particularly companies working on AI-driven drug discovery and longevity research.
Detailed Coverage
Dimension Capital, a venture capital firm established in late 2022, has successfully closed its third fund with $800 million in commitments. This amount represents a notable 60% growth compared to the firm's second fund, which stood at $500 million when it closed approximately 18 months ago. The firm is focused on investments at the intersection of science and computing, targeting early-stage companies that apply software engineering and artificial intelligence to complex biological problems.
Strategic Focus and Portfolio Performance
The firm was founded by partners Zavian Dar and Adam Goulburn, formerly of Lux Capital, and Nan Li from Obvious Ventures. Their investment strategy prioritizes the convergence of biotechnology and digital infrastructure. Market validation for this thesis has been rapid, as seen in the valuation trajectory of several portfolio companies. One notable example is Chai Discovery, which develops open-source AI models for drug development. Dimension Capital co-led a $30 million seed round for the startup in 2024, and Chai Discovery later secured $400 million in funding at a $3.8 billion valuation.
Dimension Capital also maintains a position in the longevity and anti-aging sector through its investment in New Limit. The firm participated in the company's Series A round in January 2025. Since that time, New Limit has progressed through further funding stages, reaching a valuation of $3.1 billion following its Series C round. These valuations reflect high investor appetite for companies that integrate large-scale data and computing with scientific research, a sector that has seen significant capital inflow over the last two years.
Strategic Acquisitions and Market Positioning
Beyond direct investments, Dimension Capital has benefited from consolidation within the deep-tech ecosystem. The firm received shares in the prominent AI company Anthropic following the acquisition of its portfolio entity, Coefficient Bio. This drug discovery platform was acquired in the spring of 2026 for an estimated $400 million. By securing exposure to established players like Anthropic alongside high-growth startups, the firm aims to balance its portfolio between emerging innovation and recognized AI infrastructure.
Investors looking at this space should monitor the capital efficiency and product timelines of AI-driven drug development firms. While valuations for these companies have risen sharply, the ultimate success of these businesses depends on clinical trial outcomes, regulatory approvals from health authorities, and the long-term cost-effectiveness of their AI models compared to traditional research methods. As Dimension Capital begins deploying its new $800 million fund, the firm's ability to identify companies that can successfully bridge the gap between digital compute and wet-lab biological research will remain a primary indicator of its performance.